Cardiovascular disease (CVD) and health care utilization (HCU) in patients (pts) with HR+, HER2 negative (HER2-) advanced breast cancer (ABC) on endocrine therapy with or without CDK4/6 inhibitor (CDK4/6i): A retrospective cohort study

被引：0
|
作者：
Dent, S. [1 ]
Alder, L. [1 ]
Broadwater, G. [1 ]
Hyslop, T. [1 ]
Oeffinger, K. [1 ]
Khouri, M. [1 ]
Balu, S. [2 ]
Kimmick, G. [1 ]
机构：
[1] Duke Canc Inst, Cardiooncol, Durham, NC USA
[2] Novartis Pharmaceut, HEOR, E Hanover, NJ USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
324P
引用
收藏
页码：S505 / S506
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2-Early Breast Cancer
    Klocker, Eva Valentina
    Egle, Daniel
    Bartsch, Rupert
    Rinnerthaler, Gabriel
    Gnant, Michael
    DRUGS, 2025, 85 (02) : 149 - 169
  • [42] Does HER2 Affect CDK4/6 Pathway Activity in Breast Cancer?
    Cui, Xiaoyan
    Sinclair, William
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 92 - 94
  • [43] CDK4/6 inhibitors in advanced HR+/HER2-breast cancer - a multicenter real world data analysis
    Mueller, C.
    Kiver, V
    Solomayer, E-F
    Wagenpfeil, G.
    Neeb, C.
    Blohmer, J. U.
    Abramian, A., V
    Maass, N.
    Schuetz, F.
    Kolberg-Liedtke, C.
    Ralser, D. J.
    Rambow, A-C
    BREAST CARE, 2023, 18 (01) : 31 - 41
  • [44] Does HER2 Affect CDK4/6 Pathway Activity in Breast Cancer?
    Cui, Xiaoyan
    Sinclair, William
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 92 - 94
  • [45] Health care resource utilization and costs of Medicare-enrolled patients with HR+/HER2-metastatic breast cancer treated with a CDK4/6i in the first-line setting
    Behan, Emma
    Veenstra, David L.
    Bansal, Aasthaa
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (01) : 6 - 14
  • [46] A real-world evidence study of everolimus plus endocrine therapy beyond CDK4/6 inhibitors for HR+/HER2-advanced breast cancer
    Sanchez-Bayona, Rodrigo
    Alva, Manuel
    de Sa, Alfonso Lopez
    Gilarranz, Yolanda Jerez
    de Torre, Ana Sanchez
    Tolosa, Pablo
    de Luna, Alicia
    Lopez-Tarruella, Sara
    Lema, Laura
    Moreno, Fernando
    Echavarria, Isabel
    Madariaga, Ainhoa
    Benitez, Javier
    Herrero, Blanca
    Rey, Macarena
    Ortega, Justo
    Gamez, Salvador
    Modrego, Andrea
    Lozano, Rocio Martin
    Figuero-Perez, Luis
    Jimenez, Roberto
    Sevilla, Marta Gonzalez
    Gonzalez, Irene
    Beranek, Marianela Bringas
    de Toro, Maria
    Massarrah, Tatiana
    del Monte-Millan, Maria
    Pinardo, Marina
    Manso, Luis
    Bueno-Muino, Coralia
    Garcia-Saenz, Jose Angel
    Martin, Miguel
    Ciruelos, Eva
    CANCER RESEARCH, 2023, 83 (05)
  • [47] CDK4/6 INHIBITION IMPROVES SURVIVAL IN ER+, HER2- BREAST CANCER
    不详
    CANCER DISCOVERY, 2015, 5 (02) : 107 - 107
  • [48] Discovery of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2-breast cancer
    Majeski, Hannah
    Okano, Akinori
    Chahal, Kirti
    Pasis, Angela
    Carlson, Casey
    Shakya, Arvind
    Liu, Qiao
    Huang, Shenlin
    Chourasia, Aparajita Hoskote
    Fung, Leah
    CANCER RESEARCH, 2024, 84 (09)
  • [49] Phase la study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR+/HER2-advanced breast cancer
    Zhang, Jian
    Wang, Xiaojia
    Wang, Xian
    Hui, Aimin
    Wu, Zhuli
    Tian, Ling
    Xu, Changjiang
    Yang, Yuchen
    Zhang, Wenjing
    Hu, Xichun
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1549 - 1558
  • [50] Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database
    Stephanie H. Read
    Nadia Quignot
    Raissa Kapso-Kapnang
    Erin Comerford
    Ying Zheng
    Corona Gainford
    Medha Sasane
    Anne-Lise Vataire
    Laure Delzongle
    Francois-Clement Bidard
    Breast Cancer Research and Treatment, 2024, 204 : 579 - 588
12345